Trial reportAlzheimer's research & therapy2015
Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software.
Trial report in Alzheimer's research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- The Effect of Chronic Alprazolam Intake on Memory, Attention, and Psychomotor Performance in Healthy Human Male Volunteers.Behavioural neurology · 2016Trial
- Causal relationship between proton pump inhibitors and dementia risk: evidence from a Mendelian randomization study.European archives of psychiatry and clinical neuroscience · 2025Article
- Review
- The Cognitive Footprint of Medication Use.Brain and behavior · 2025Article
- The impact of proton pump inhibitors on brain health based on cross-sectional findings from the Rhineland Study.Scientific reports · 2024Article
- Article
- Proton pump inhibitors and dementia: A nationwide population-based study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Impaired Executive Functioning Associated with Alcohol-Related Neurocognitive Disorder including Korsakoff's Syndrome.Journal of clinical medicine · 2023Article
- Article
- Proton Pump Inhibitor Use and Cognitive Function in the Boston Puerto Rican Health Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023Article
- Hippocampal synaptic dysfunction and spatial memory impairment in omeprazole-treated rats.Metabolic brain disease · 2022Article
- Regular proton pump inhibitor use and incident dementia: population-based cohort study.BMC medicine · 2022Article
- Associations between proton pump inhibitors and Alzheimer's disease: a nested case-control study using a Korean nationwide health screening cohort.Alzheimer's research & therapy · 2022Article
- Association between Proton Pump Inhibitor Use and Parkinson's Disease in a Korean Population.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Mechanistic Link between Vitamin B12 and Alzheimer's Disease.Biomolecules · 2022Review
- Gastric acid suppressants and cognitive decline in people with or without cognitive impairment.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- Lack of association between proton pump inhibitor use and decline in cognitive performance in the ELSA-Brasil cohort.European journal of clinical pharmacology · 2021Article
- A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data.Scientific reports · 2021Article
- Elevated anxiety, hypoactivity, memory deficits, decreases of brain serotonin and 5-HT-1A receptors expression in rats treated with omeprazole.Toxicological research · 2021Article
- CSF and Plasma Cholinergic Markers in Patients With Cognitive Impairment.Frontiers in aging neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionStudies have shown that proton pump inhibitors (PPIs) increase the brain burden of amyloid-beta (Aβ) and also create vitamin B12 deficiency. However, these two phenomena have deleterious effect on cognition and Alzheimer's disease (AD). Since the use of PPIs has increased tremendously for the last few years, it is of great public health importance to investigate the cognitive impact of PPIs. Hence, the purpose of this study was to investigate the degree of neuropsychological association of each PPI with different cognitive functions.
methodsSixty volunteers of either gender were recruited and divided randomly into six groups: five test groups for five classes of PPIs and one control group. All the groups participated in the five computerized neuropsychological tests (nine subtests) of the Cambridge Neuropsychological Test Automated Battery twice: at the beginning of the study and 7 days thereafter.
resultsWe found statistically and clinically significant impairment in visual memory, attention, executive function, and working and planning function. One-way analysis of variance findings showed that all PPIs had a similar negative impact on cognition. However, paired-samples t tests indicated that omeprazole showed significant (p < 0.05) results in seven subtests; lansoprazole and pantoprazole showed significant results in five subtests; and rabeprazole showed significant results in four subtests. Among five classes of PPIs, esomeprazole showed comparatively less impact on cognitive function with significant results in three subtests.
conclusionsThe present study reveals for the first time that different PPIs have varying degrees of influence on different cognitive domains and have associations with AD. These findings should be considered when balancing the risks and benefits of prescribing these medications. A study done for a longer period of time with a larger sample size might yield better results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.